Prediction models for development of hepatocellular carcinoma in chronic hepatitis B patients

Table 3 Risk scores for prediction of hepatocellular carcinoma in treated chronic hepatitis B patients during treatment

Ref.	Score	Patients in derivation, n	Country or area	Age (yr)	HBeAg-positive, n (%)	Cirrhosis in derivation, n (%)	Follow-up (yr), median	Variables of the risk score	AUROC for 5 yr	Cut-off
Chen et al[54]	APA-B	883	Taiwan	50 ± 17	311 (35.2)	317 (35.9)	4.1	Age, platelets, AFP at 12 mo	0.827	Low-risk 0-5; Intermediate risk 6-9; High risk 10-15
Lim et al[56]	HCC-ESCAVT	769	South Korea	47.0 (37.0-55.0)	0	319 (41.5)	-	Sex, age, cirrhosis, ALT, AST, platelet	0.771	Low-risk 0-1; Intermediate risk 2-4; High risk 5
Papatheodoridis et al[58]	CAGE-B	1427	Europe	52.1 ± 13.1	261 (18.4)	370 (25.9)	8.4	Age, LSM at year 5, baseline cirrhosis	0.814	Low-risk 0-5; Intermediate risk 6-10; High risk 11-16
Papatheodoridis et al[58]	SAGE-B	1427	Europe	52.1 ± 13.1	261 (18.4)	370 (25.9)	8.4	Age, LSM at year 5	0.809	Low-risk 0-5; Intermediate risk 6-10; High risk 11-16

HBeAg: Hepatitis B e antigen; AUROC: Area under the receiver operating characteristic curve; HCC: Hepatocellular carcinoma; ESC: Hepatitis B e antigen seroclearance; AVT: Antiviral therapy; CAGE-B: Cirrhosis and age; SAGE-B: Stiffness and age; AFP: α-Fetoprotein; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; LSM: Liver stiffness measurement.